NYSE:ZTSPharmaceuticals
Is Zoetis’ (ZTS) OptiCell Upgrade Quietly Rebalancing Its Innovation And Recurring Revenue Mix?
Zoetis recently expanded the capabilities of its AI-powered Vetscan OptiCell hematology analyzer, while investors and analysts have turned their attention to its upcoming May 7 earnings release and evolving product portfolio.
The combination of point-of-care diagnostics innovation and heightened expectations around earnings and companion animal growth is sharpening focus on how Zoetis’ business mix may be evolving.
We’ll now examine how the Vetscan OptiCell upgrade could influence Zoetis’...